FTO.nl maakt op haar websites gebruik van cookies. Een cookie is een klein bestandje dat met een pagina van een website wordt meegestuurd en door uw browser (tijdelijk) op de harde schrijf van uw computer of mobiele apparatuur wordt opgeslagen.
NHG-Standaard Diabetes mellitus type 2. Vierde (partiële) herziening, 2018.
Jansen RT, Slingerland RJ. SKML-Quality Mark for point-of-care test (POCT) glucose meters and glucose meters for home-use. Clin Chem Lab Med. 2010;48:1021-7.
Verenso multidisciplinaire richtlijn 2011, “Verantwoorde diabeteszorg bij kwetsbare ouderen in thuissituatie, verzorgingshuis- en verpleeghuizen”.
Verhoeven S, Kleefstra N, Bilo HJG, et al. Diabeteszorg aan het eind van het leven, een handleiding voor de praktijk, 2013.
Eerste Associatie van diabeteszorgverleners (EADV). Multidisciplinaire richtlijn over zelfcontrole van de bloedglucosewaarden door mensen met diabetes. Juni 2012. Beschikbaar via: https://www.nvkc.nl/sites/default/files/12.pdf.
Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med. 2001;111:1-9.
Murata GH, Shah JH, Hoffman RM, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care. 2003;26:1759-63.
Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med. 1993, 329:977-986.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008,9; 359(15):1577-1589.
Hortensius J. Self-monitoring of blood glucose in insulin-treated patients with diabetes. Proefschrift RUG: 2013.
Berlin I, Bisserbe J-C, Eiber R, et al. Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. Diabetes Care. 1997;20:176–178.
Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabet Med. 2018; 35:472-482.
De Valk HW. Insulin pump regulated by a glucose sensor; one step closer to closing the loop for type 1 diabetes patients. Ned Tijdschr Geneeskd. 2019 Sep 24;163:D3713.
Advani A. Positioning time in range in diabetes management. Diabetologia (2020) 63:242–252.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA 2017;317:371–378.
Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA 2017;317:379–387.
Tauschmann M, Thabit H, Bally L, et al; APCam11 Consortium. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018;392:1321-9.
Rodbard D. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. Diabetes Technol Ther. 2017;19(S3):S25-S37.
Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care. 2019;7:e000809.
FTO Onderwerpen
FTO
